http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Polymorphisms in Apoptosis-Related Genes and TP53 Mutations in Non-Small Cell Lung Cancer
배은영,이은진,강효경,이신엽,Gwang Jin,이원기,최진은,전효성,임정옥,이응배,박재영 대한의학회 2011 Journal of Korean medical science Vol.26 No.11
Apoptosis plays an essential role in the elimination of mutated or transformed cells from the body. Therefore, polymorphisms of apoptosis-related genes may lead to an alteration in apoptotic capacity, thereby affecting the occurrence of TP53 mutations in lung cancer. We investigated the relationship between potentially functional polymorphisms of apoptosis-related genes and TP53 mutations in non-small cell lung cancer (NSCLC). Twenty-seven single nucleotide polymorphisms in 20 apoptosis-related genes were genotyped by a sequenome mass spectrometry-based genotyping assay in 173 NSCLCs and the associations with TP53 mutations in the entire coding exons (exons 2-11), including splicing sites of the gene, were analyzed. None of the 27 polymorphisms was significantly associated with the occurrence of TP53 mutations. This suggests that apoptosis-related genes may not play an important role in the occurrence of TP53 mutations in lung cancer.
배은영 서울大學校保健大學院 1997 國民保健硏究所硏究論叢 Vol.7 No.1
The pharmacy insurance system was intrduced in 1989 to cover pharmacist's dispensing services. Though the number of cases for reimbursement has highly increased since 1993, the performance of the pharmacy insurance system is still very weak. This study intends to investigate the economic rationality of the current pharmacy insurance system. To evaluate the system, this study investigates (i) whether demand for pharamcy would be a substitute for demand for clinical services, and (ii) whether the introduced system would induce optimal drug use by consumers. Also, this study evaluates the pharmacy insurance system on the basis of risk insurance, and income redistribution. The result shows that the pharmacy insuance system has a weak economic basis.
배은영,Bae, Eun-Young 대한예방의학회 2008 예방의학회지 Vol.41 No.2
An economic evaluation is required in order to apply to the Health Insurance Review and Assessment Service (HIRA) for a listing in the national drug formulary. To assist companies in preparing the necessary documents, HIRA published guidelines for the economic evaluation of pharmaceuticals in 2006. The guidelines are composed of two parts: guidance and explanatory notes. Each guideline reflects the best practice which meets both the theoretical consensus within the academic community and local situations, like data availability. To enhance the transparency of evaluation, guidelines emphasize the reproducibility of data and analysis result. That is, all evaluation processes are required to be described in enough detail to be replicated by reviewers. With growing experience and theoretical development in this area, HIRA guidelines will be revised periodically.